EE05020B1 - Glburiidi ravimkoostis - Google Patents

Glburiidi ravimkoostis

Info

Publication number
EE05020B1
EE05020B1 EEP200200393A EEP200200393A EE05020B1 EE 05020 B1 EE05020 B1 EE 05020B1 EE P200200393 A EEP200200393 A EE P200200393A EE P200200393 A EEP200200393 A EE P200200393A EE 05020 B1 EE05020 B1 EE 05020B1
Authority
EE
Estonia
Prior art keywords
g1buride
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
EEP200200393A
Other languages
English (en)
Estonian (et)
Inventor
Cave Gillian
J. Nicholson Sarah
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200393A publication Critical patent/EE200200393A/xx
Publication of EE05020B1 publication Critical patent/EE05020B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200200393A 2000-01-14 2001-01-04 Glburiidi ravimkoostis EE05020B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48370300A 2000-01-14 2000-01-14
PCT/US2001/000234 WO2001051463A1 (en) 2000-01-14 2001-01-04 Glyburide composition

Publications (2)

Publication Number Publication Date
EE200200393A EE200200393A (et) 2003-10-15
EE05020B1 true EE05020B1 (et) 2008-06-16

Family

ID=23921174

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200393A EE05020B1 (et) 2000-01-14 2001-01-04 Glburiidi ravimkoostis

Country Status (37)

Country Link
US (2) US20010036479A1 (es)
EP (1) EP1250321B1 (es)
JP (1) JP4787446B2 (es)
KR (1) KR100739906B1 (es)
CN (1) CN1210258C (es)
AR (1) AR031547A1 (es)
AT (1) ATE330937T1 (es)
AU (1) AU771705B2 (es)
BG (1) BG65782B1 (es)
BR (1) BR0107564A (es)
CA (1) CA2397294C (es)
CY (1) CY1106328T1 (es)
CZ (1) CZ20022429A3 (es)
DE (1) DE60120916T2 (es)
DK (1) DK1250321T3 (es)
EE (1) EE05020B1 (es)
ES (1) ES2264967T3 (es)
GE (1) GEP20043299B (es)
HU (1) HU228825B1 (es)
IL (2) IL150383A0 (es)
LT (1) LT5024B (es)
LV (1) LV12914B (es)
MX (1) MXPA02006835A (es)
MY (1) MY128577A (es)
NO (1) NO328152B1 (es)
NZ (1) NZ519920A (es)
PT (1) PT1250321E (es)
RO (1) RO121381B1 (es)
RU (1) RU2244707C2 (es)
SK (1) SK286925B6 (es)
TN (1) TNSN01005A1 (es)
TR (1) TR200201798T2 (es)
TW (1) TWI287989B (es)
UA (1) UA73968C2 (es)
UY (1) UY26529A1 (es)
WO (1) WO2001051463A1 (es)
ZA (1) ZA200205528B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
WO2003080056A2 (en) * 2002-03-21 2003-10-02 Teva Pharmaceutical Industries Ltd. Fine particle size pioglitazone
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN100455279C (zh) * 2004-04-29 2009-01-28 美时化学制药股份有限公司 口服延迟释放锭剂组成物及其制法
CA2563325C (en) * 2004-04-29 2010-06-22 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) * 2005-04-11 2006-10-19 Aurobindo Pharma Limited Solid dosage form of an antidiabetic drug
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
NZ565955A (en) 2005-08-22 2011-08-26 Melior Pharmaceuticals I Inc Methods and formulations for modulating lyn kinase activity and treating related disorders
CN101287467B (zh) * 2005-08-22 2011-01-19 梅里奥尔医药I公司 用于调节Lyn激酶活性和治疗相关病症的方法和制剂
US20090252790A1 (en) * 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2010048287A2 (en) 2008-10-22 2010-04-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Radioprotective agents
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) * 2012-07-31 2012-10-24 南京正科制药有限公司 瑞格列奈片及其制备方法
CN103142521B (zh) * 2013-03-21 2014-06-25 西南药业股份有限公司 格列本脲片及其制备方法
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN104127423A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列喹酮衍生物及其制备方法和应用
NZ758966A (en) 2017-04-10 2024-08-30 Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Treatment of adipocytes
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法
WO2023012610A1 (en) * 2021-08-03 2023-02-09 Avaca Pharma Private Limited Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en) 1970-09-10 1972-01-04 Frank W. Horner Limited Purification of glyburide
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) * 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) * 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru) 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en) 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DE59206324D1 (de) * 1991-12-05 1996-06-20 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
WO1998057634A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
DE69811233T2 (de) * 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
EP0974356B1 (en) 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Also Published As

Publication number Publication date
NO20023367D0 (no) 2002-07-12
ATE330937T1 (de) 2006-07-15
IL150383A0 (en) 2002-12-01
CA2397294C (en) 2011-03-22
PT1250321E (pt) 2006-09-29
EP1250321A1 (en) 2002-10-23
US20010036479A1 (en) 2001-11-01
GEP20043299B (en) 2004-03-10
CY1106328T1 (el) 2011-10-12
ES2264967T3 (es) 2007-02-01
LT2002085A (en) 2003-01-27
PL356210A1 (en) 2004-06-14
RU2244707C2 (ru) 2005-01-20
HU228825B1 (en) 2013-05-28
LT5024B (lt) 2003-06-25
KR20020073169A (ko) 2002-09-19
BR0107564A (pt) 2002-10-01
AU771705B2 (en) 2004-04-01
TR200201798T2 (tr) 2002-11-21
US20030185880A1 (en) 2003-10-02
CN1210258C (zh) 2005-07-13
SK9832002A3 (en) 2003-07-01
RO121381B1 (ro) 2007-04-30
RU2002121626A (ru) 2004-01-10
DK1250321T3 (da) 2006-07-31
CZ20022429A3 (cs) 2003-06-18
BG65782B1 (bg) 2009-11-30
NO328152B1 (no) 2009-12-21
JP4787446B2 (ja) 2011-10-05
US6830760B2 (en) 2004-12-14
IL150383A (en) 2007-03-08
TNSN01005A1 (en) 2005-11-10
CA2397294A1 (en) 2001-07-19
MXPA02006835A (es) 2003-01-28
DE60120916T2 (de) 2007-02-15
BG106870A (en) 2003-03-31
ZA200205528B (en) 2003-10-10
DE60120916D1 (de) 2006-08-03
EP1250321B1 (en) 2006-06-21
WO2001051463A1 (en) 2001-07-19
SK286925B6 (sk) 2009-07-06
TWI287989B (en) 2007-10-11
HUP0203852A2 (hu) 2003-04-28
LV12914B (en) 2003-01-20
CN1395560A (zh) 2003-02-05
EE200200393A (et) 2003-10-15
AR031547A1 (es) 2003-09-24
AU2474001A (en) 2001-07-24
UY26529A1 (es) 2001-08-27
UA73968C2 (en) 2005-10-17
MY128577A (en) 2007-02-28
JP2003519681A (ja) 2003-06-24
NZ519920A (en) 2004-06-25
NO20023367L (no) 2002-09-04
KR100739906B1 (ko) 2007-07-16
HUP0203852A3 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
DK1524266T3 (da) Farmaceutisk sammensætning
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
EE05020B1 (et) Glburiidi ravimkoostis
NO20025450L (no) Ny farmasöytisk sammensetning
ITMI20010748A0 (it) Composizioni farmaceutiche
FI20011478A (fi) Farmaseuttinen koostumus
NO20015175L (no) Farmasöytisk sammensetning
ITTO20010008A0 (it) Formulazione farmaceutica
FI991485A0 (fi) Uusi farmaseuttinen koostumus
PT1242087E (pt) Composicoes farmaceuticas
EE200300416A (et) Ravimvorm
DK1395242T3 (da) Flydende farmaceutisk sammensætning
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A (fi) Farmaseuttinen koostumus
PT1239832E (pt) Composicoes farmaceuticas
NO20031095L (no) Farmasoytiske sammensetninger
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
FI4488U1 (fi) Farmaseuttinen koostumus
DE10291905D2 (de) Pharmazeutische Zusammensetzung
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
EE200200689A (et) Ravimkoostised
DE10107261B4 (de) Pharmazeutische Zusammensetzung
FI5468U1 (fi) Farmaseuttinen koostumus

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231